BHVN
Biohaven Ltd.
NYSE · Healthcare · Biotechnology · US
$11.35
+5.29%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +26.1%
- EBIT
- +29.2%
- EPS
- +39.4%
- Free cash flow
- +20.8%
- Operating cash flow
- +20.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +42.5%
- EPS
- +51.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- +13.2%
- EBIT
- +15.8%
- Net income
- +12.7%
- EPS
- +26.1%
- Free cash flow
- -4.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026